A gold-gadolinium (III) NPs (Au-Gd (III)-PSMA) targeting PSMA (highly expressed in prostate cancer) was synthesized to selectively deliver gadolinium (III) contrast agents to prostate cancer.866 The results indicated that the gold-gadolinium (III) PSMA NPs showed favorable tumor accumulation, and enhanced the cell’s magnetic resonance contrast and radio-sensitization, meanwhile they also reduced the damage to the surrounding normal tissues. This evidence concerns the gene FOLH1 and prostate cancer.